BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29274586)

  • 1. Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease.
    Kumar K; Kumar A; Keegan RM; Deshmukh R
    Biomed Pharmacother; 2018 Feb; 98():297-307. PubMed ID: 29274586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
    Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
    Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron.
    Saeedi M; Rashidy-Pour A
    Biomed Pharmacother; 2021 Jan; 133():110995. PubMed ID: 33232931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models.
    Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29168797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer disease therapeutics.
    Irizarry MC; Hyman BT
    J Neuropathol Exp Neurol; 2001 Oct; 60(10):923-8. PubMed ID: 11589422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau.
    Castellani RJ; Lee HG; Perry G; Smith MA
    Am J Alzheimers Dis Other Demen; 2006; 21(2):126-30. PubMed ID: 16634469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
    Xie Y; Tan Y; Zheng Y; Du X; Liu Q
    J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiology and pharmacotherapy of Alzheimer's disease.
    Felician O; Sandson TA
    J Neuropsychiatry Clin Neurosci; 1999; 11(1):19-31. PubMed ID: 9990552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future Therapeutic Perspectives into the Alzheimer's Disease Targeting the Oxidative Stress Hypothesis.
    Teixeira JP; de Castro AA; Soares FV; da Cunha EFF; Ramalho TC
    Molecules; 2019 Dec; 24(23):. PubMed ID: 31816853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease.
    Castro A; Conde S; Rodriguez-Franco MI; Martinez A
    Mini Rev Med Chem; 2002 Feb; 2(1):37-50. PubMed ID: 12369956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
    Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
    Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.
    Liu Z; Li T; Li P; Wei N; Zhao Z; Liang H; Ji X; Chen W; Xue M; Wei J
    Oxid Med Cell Longev; 2015; 2015():352723. PubMed ID: 26171115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease: emerging trends in small molecule therapies.
    Mohamed T; Rao PP
    Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.